23 Stock Top Picks and 7 ETF (Nov 30 Dec 6)

It's really struggling for the next product. Just doesn't see sustainable growth without a new product to lift earnings. Apple Services is definitively going to be a good driver, but thinks there are other opportunities elsewhere. He has an Android phone, doesn't see why someone would pay $1,500 for a new iPhone and be locked…

It sold off a few days ago but it came back. It is overbought. It has been overbought for a while. The trend is good.

There are three interesting sectors: The traditional utilities that are rather overvalued; the telcos in Canada are good plays. They are not fully valued but not cheap; The pipelines are more linked to energy prices. He would agree that the sectors are fairly fully valued but he likes that it is defensive and has a…

DEX Floating Rate ETF (XFR-T) or Vanguard Cdn. Aggregate Bond ETF (VAB-T)? If interest rates rise, which would you Buy? The aggregate bond is a little bit longer in duration with an average of 6 or 7 years and might be a little bit more sensitive to interest rate hikes so this one might be…

A simple basket of US names that have a history of increasing their dividends over the last 10 consecutive years. As US interest rates move higher, he thinks dividend growth companies will outperform those with little or no dividend growth. Year-to-date and over the past year, this has outperformed the broader S&P 500.

Expensive right, now trading at over 20X PE, and they are slow growing stocks. But, in the summer months, investors are willing to pay a little more for that stability.

It is not unlike a REIT but for pipelines in the US. They put it into this MLP structure. It is a basket of pipeline stocks. The revenue gets passed on to the shareholder. It is not a Canadian dividend, however, so not taxed the same way. He thinks you are in a trading range…

Their real estate exposure is US: Industrial, healthcare, office and digital data centers. He prefers this one because it has a bigger share of the specialized REIT sector.

(A Top Pick April 18/16. Up 8%.) If this can get above the peak it hit in March, it is going to really accelerate. He would like this one longer-term. (See Top Picks.)

TD-T vs. RY-T. TD-T is bigger than RY-T in the US. BNS-T is a bit cheaper. He is warming up to the sector in general.

A spin-off of Brookfield Asset Management. For every 170 shares of BAM-T one owned, they received one share of TSU-T. They underwrite smaller BTB insurance. They can sell-off re-insurance for a recurring fee stream in the US – a process called “fronting”. On paper it looks like they operate at a loss, but it will…

The NASDAQ has been on fire and this represents that as a proxy. It is back to recent highs, so he would wait for a break to new highs, wait two days and then buy if it holds strength. He would not buy until the new highs have been made.

(A Top Pick Jun 08/18, Up 8%) Half of the gain was from the dividend. They have posted earnings growth of 7% over the year. They are trading below historical multiples. About 23% of earnings come from the US. She thinks they will continue to increase the dividend.

Cheap at 9 X earnings with a 2 1/2% dividend. Florida insurance is under a seperate entity, so hurricane is not a problem.

His analyst met with them yesterday and it made him feel very bullish. Operationally they have been very strong. They added to their holding a few weeks ago. He thinks it could get back to $12 soon. The multiples are improving the value in his eyes and thinks the market will reward them. Rental rates…

A sub-sector he likes in the U.S. are single-family homes. Institutional investors bought up distressed homes during the Recession, then rented out those homes after that period. INVH is a major player in this space and it's trading at a discount to NAV now.

They specialize in technology and life-sciences clusters. Their tenants will be repatriation cash, so ARE's partnership with these tenants will create value and rent growth. (2.9% dividend yield)

Had a tremendous run up to about $12, but got completely blindsided, and it pulled back heavily. Got stopped out around mid-$6. Thinks they are going to be okay long-term. There were some issues with insider selling at higher levels. If you own, continue to hold as it looks like it has bottomed.

It's the old Valeant. It has a future, cleaned up their act, but too much debt. Stable now, so maybe good for the long-term, certainly better than the Valeant days.

Just tested the 50- and 100-week moving averages--and hasn't broken them. It's still cheap after selling off, building a base and is now moving up.

(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the…

He thinks the worst of the drugs going off patent is over. These guys have been really hurt by their patent cliff. It is a really good value name. He sees resistance at $67. It is a good sector to be in. (Analysts’ target: $68.79).

Hasn't had his name in his portfolio for the last 5 years so can't say a lot about it. Pays a high dividend yield (5.3%) but it doesn't have a lot of growth, which concerns him. Had some negative earnings surprises over the years that scare him.

Healthcare in general has outperformed in every bear market. A lot of it comes from large cap pharma companies. He prefers LLY-N. But there is no question that this one is interesting and has good management.

She expects them to be reporting earnings in the next couple of days. This bus manufacturing company has made a purchase in the UK for double-decker buses. This is not a great growth sector. She wants to see how the recent acquisition plays out.

Global leader of valves from Montreal. Classic value play, trading just above 1 times NAV. They report in US dollars. About 11 times earnings. The founder is 97 years old. If it is ever sold he figures it could get as much as $30 a share.

Global Japanese company. Makes equipment to test environmental equipment. Growing revenues around 10% a year, and bottom line by 10-15% a year. On sale. Lots of cash. Amazingly cheap and unique. Yield is 3.1%. (Analysts’ price target is $2800.00)

Over the last 12 to 24 months has had a number of reimbursement cuts or rumours of them. It is now trading at a cheap valuation. Assuming no more cuts, then they should be starting to build on that. In recent earnings surgical centers were stronger than analysts expected. They have a new product to…

(A Top Pick Jul 31/18, Up 34%) Great management, but it is getting too expensive at 22 times earnings. A couple of weak quarters has caused a recent pullback. They are good at what they do. Still a core holding, but he may reduce his position soon.

Well run. To make money in the long run, you have to be a counter-cyclical acquirer like Suncor. If you're holding it for income, you might want to stick with it. Resilient cash flow profile. But as a total return growth stock, better opportunities elsewhere. Shareholder friendly. Yield is north of 4%. One concern is…